^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    darlifarnib (KO-2806)

    i
    Other names: KO-2806
    Associations

    News

    Trials
    Company:
    Kura Oncology
    Drug class:
    Farnesyl transferase inhibitor
    Related drugs:
    Associations

    News

    Trials
    1m
    The farnesyl transferase inhibitor darlifarnib (KO-2806) re-sensitizes relapsing tumors to RAS inhibition. (PubMed, Cancer Res)
    Further, the addition of KO-2806 rescued sensitivity of progressing tumors to the pan-RAS inhibitor RMC-6236. These results establish mTORC1 as an important mediator of escape from RAS inhibition and highlight KO-2806 as a promising RAS companion inhibitor in patients with prior RAS inhibitor exposure.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • RHEB (Ras Homolog, MTORC1 Binding)
    |
    KRAS mutation • RAS mutation
    |
    daraxonrasib (RMC-6236) • darlifarnib (KO-2806)
    2years
    FIT-001: KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=270, Recruiting, Kura Oncology, Inc.
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    KRAS mutation • HRAS mutation • HRAS overexpression
    |
    Cabometyx (cabozantinib tablet) • darlifarnib (KO-2806)
    over2years
    FIT-001: KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=270, Recruiting, Kura Oncology, Inc. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    KRAS mutation • HRAS mutation • HRAS overexpression
    |
    Cabometyx (cabozantinib tablet) • darlifarnib (KO-2806)
    over2years
    FIT-001: KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=270, Not yet recruiting, Kura Oncology, Inc.
    New P1 trial • Combination therapy • Metastases
    |
    KRAS (KRAS proto-oncogene GTPase) • NRAS (Neuroblastoma RAS viral oncogene homolog) • HRAS (Harvey rat sarcoma viral oncogene homolog)
    |
    KRAS mutation • HRAS mutation • HRAS overexpression
    |
    Cabometyx (cabozantinib tablet) • darlifarnib (KO-2806)